Trials & Litigation

Negative Vytorin Study Prompts Lawsuits

Reports that Vytorin is no more effective than generic drugs in battling cholesterol have already generated lawsuits.

The suits claim drug makers Merck & Co. Inc. and Schering-Plough Corp. delayed release of the negative study while touting the drug’s benefits, the National Law Journal reports.

Lawyer Steve Berman of Seattle filed a federal suit on Jan. 17 in New Jersey. The same day lawyer David Rheingold filed suit on behalf of his wife, a Vytorin user, in federal court in New York.

Berman’s suit seeks refunds for consumers who bought the drug. “They were paying out of pocket because they were told [Vytorin] would lower their plaque,” he told the newspaper. “They wouldn’t have paid for it if the drug was truthfully marketed.”

We welcome your comments, but please adhere to our comment policy and the ABA Code of Conduct.

Commenting is not available in this channel entry.